EXELON 4.5 MG
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 4.5 MG · DIN 02242117 · KNIGHT THERAPEUTICS INC.
Health Canada status: MARKETED
What is EXELON?
EXELON 4.5 MG contains RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 4.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02242117, held by KNIGHT THERAPEUTICS INC., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Nov-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EXELON used for?
EXELON® (rivastigmine hydrogen tartrate) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type, and for the symptomatic treatment of patients with idiopathic Parkinson’s disease, and mild to moderate dementia, with onset at least 2 years after the initial diagnosis of Parkinson’s disease, and in whom other causes of dementia have been ruled out.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is EXELON called?
The same molecule, RIVASTIGMINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| NIMVASTID | Latin | Czechia |
| Zeyzelf | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02242117 |
|---|---|
| Brand name | EXELON |
| Generic / active ingredient | RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 4.5 MG |
| Manufacturer | KNIGHT THERAPEUTICS INC. |
| Strength | 4.5 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06DA03 RIVASTIGMINE |
| AHFS class | 12:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Nov-2022 |
| Original market date | 2000-05-15 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02242117 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2242117 |
| Brand name | EXELON |
| Active ingredient / INN | RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 4.5 MG |
| ATC code | N06DA03 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06 |
| AHFS class | 12:04.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | KNIGHT THERAPEUTICS INC. |
How is it stored and handled?
null
How is it supplied?
Capsules: 4 blister strips of 14 capsules each (total 56 capsules per carton). Oral Solution: 120 mL per bottle.
Which pack is which?
| Strength on the label | 4.5 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Packaging as described in the monograph | Capsules: 4 blister strips of 14 capsules each (total 56 capsules per carton). Oral Solution: 120 mL per bottle. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code N06DA03 RIVASTIGMINE. 28 of 80 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-RIVASTIGMINE | 1.5 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02336715 |
| APO-RIVASTIGMINE | 3 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02336723 |
| APO-RIVASTIGMINE | 4.5 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02336731 |
| APO-RIVASTIGMINE | 6 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02336758 |
| EXELON | 1.5 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02242115 |
| EXELON | 2 MG | SOLUTION | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02245240 |
| EXELON | 3 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02242116 |
| EXELON | 6 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02242118 |
| EXELON PATCH 10 | 9.5 MG / 24 HOUR | PATCH | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02302853 |
| EXELON PATCH 15 | 13.3 MG / 24 HOUR | PATCH | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02432803 |
Who else supplies RIVASTIGMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIVASTIGMINE appears in 242 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does RIVASTIGMINE cost around the world?
RIVASTIGMINE is listed on 12 national price registers Nexara tracks, across 213 pack listings published on 11 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 7 | 66 | 03 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 33 | 43 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 22 | 22 | 03 Sep 2026 |
| Saudi Arabia | public | 17 | 19 | 01 Sep 2026 |
| Australia | ex-manufacturer | 4 | 14 | 08 Sep 2026 |
| Czechia | max producer price (ex-factory) | 2 | 14 | 03 Sep 2026 |
| United Kingdom | hospital | 8 | 8 | 31 Aug 2026 |
| Luxembourg | reimbursement | 8 | 8 | 05 Sep 2026 |
| South Africa | single exit price | 7 | 8 | 01 Sep 2026 |
| Hungary | producer price (ex-factory) | 5 | 7 | 03 Sep 2026 |
| Bahrain | retail (max) | 1 | 2 | 01 Sep 2026 |
| Morocco | PPV (public price) | 2 | 2 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.